Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Akebia Therapeutics, Inc. (AKBA) had Revenue of $57.34M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$57.34M
Net Income	$6.11M
Cost of Goods Sold	$7.62M
Gross Profit	$49.71M
Operating Expenses	$43.82M
Operating Income	$13.51M
Non-Operating Income/Expense	$-7.40M
Pre-Tax Income	$6.11M
Normalized Pre-Tax Income	$6.11M
Income after Taxes	$6.11M
Income from Continuous Operations	$6.11M
Consolidated Net Income/Loss	$6.11M
Normalized Income after Taxes	$6.11M
EBIT	$13.51M
EBITDA	$13.83M
Weighted-Average Shares Outstanding (Basic)	235.50M
Weighted-Average Shares Outstanding (Diluted)	241.60M
Earnings per Share (EPS) (Basic)	$0.03
Earnings per Share (EPS) (Diluted)	$0.03
Balance Sheet Financials
Current Assets	$203.78M
Property, Plant, and Equipment	$1.90M
Long-Term Assets	$106.40M
Total Assets	$310.19M
Current Liabilities	$91.23M
Long-Term Debt	$46.51M
Long-Term Liabilities	$194.38M
Total Liabilities	$285.60M
Common Equity	$24.58M
Tangible Shareholders Equity	$-34.46M
Shareholders Equity	$24.58M
Common Shares Outstanding	261.64M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-13.59M
Cash Flow from Investing Activities	$0.15M
Cash Flow from Financial Activities	$74.94M
Beginning Cash	$53.55M
End Cash	$115.06M
Increase/Decrease in Cash	$61.51M
Stock-Based Compensation	$2.19M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.23
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.65
Debt to Equity Ratio	1.89
Gross Margin	86.70%
Operating Margin	23.57%
EBIT Margin	23.57%
EBITDA Margin	--
Pre-Tax Profit Margin	10.66%
Profit Margin	10.66%
Free Cash Flow	$-13.43M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.18
Inventory Turnover	0.39
Receiveable Turnover	0.93
Days Sales in Receivables	96.60
Return on Equity	24.86%
Return on Tangible Equity	-17.73%
Return on Assets	1.97%
Return on Investments	8.60%
Book Value Per Share	$0.09
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.06

Data from Zacks Investment Research, Inc.